COVID19: Structure of COVID19 SARS-CoV-2 Spike protein in complex with monoclonal antibodies.
EMSL Project ID
51528
Abstract
The ongoing global outbreak of atypical pneumonia (COVID-19) is caused by a newly emerged zoonotic beta coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). On March 11th, 2020, the World Health Organization declared COVID-19 a pandemic (2) and as of April 30th, 2020, over 3 M people were estimated to have been infected and over 200, 000 people had died (3). There is currently no vaccine available to prevent infection with SARS-CoV-2 or therapeutics. It is also unclear which types of immune responses are required to prevent or control infection. Our team has isolated monoclonal antibodies from infected COVID-19 patients. The goal of this project is to identify critical sites of vulnerability on SARS-CoV-2 S glycoproteins through structure/function analyses of monoclonal antibodies developed during natural infection. Such antibodies can be employed as preventive or therapeutic agents. Moreover, structurally defining critical sites of vulnerability on SARS-CoV-2 will facilitate the development of an effective vaccine against this pathogen.
Project Details
Start Date
2020-06-27
End Date
2021-03-17
Status
Closed
Released Data Link
Team
Principal Investigator
Team Members